original ) (raw )Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody
Marek Pruszyński , Eftychia Koumarianou
Nuclear Medicine and Biology, 2013
View PDFchevron_right
Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling
Eftychia Koumarianou , Marek Pruszyński
Journal of Nuclear Medicine, 2014
View PDFchevron_right
Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer
Nick Devoogdt , I. Vaneycken , Cécile Vincke
The FASEB Journal, 2011
View PDFchevron_right
Phase I study of 68Ga-HER2-Nanobody for PET/CT assessment of HER2-expression in breast carcinoma
Ilse Vaneycken
Journal of Nuclear Medicine
View PDFchevron_right
Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers
Darryl McDougald
Scientific Reports
View PDFchevron_right
Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by ImmunoPET
Darryl McDougald
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016
View PDFchevron_right
HER2 Expression in Breast Cancer Cells Is Downregulated Upon Active Targeting by Antibody-Engineered Multifunctional Nanoparticles in Mice
Raffaele Allevi
ACS Nano, 2011
View PDFchevron_right
Development of 177 Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators
Marlies Gijs
Contrast Media & Molecular Imaging, 2012
View PDFchevron_right
Targeting HER2+ breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles
Shawn Owen
Journal of Controlled Release, 2013
View PDFchevron_right
Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent
Darryl McDougald
Nuclear Medicine and Biology, 2020
View PDFchevron_right
Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors
Andres J P Klein-Szanto
Cancer Research, 2011
View PDFchevron_right
Molecular imaging of tumors with nanobodies and antibodies: Timing and dosage are crucial factors for improvedin vivodetection
Harald Ittrich
Contrast Media & Molecular Imaging, 2015
View PDFchevron_right
Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer
Sukhen Ghosh
Molecular Imaging
View PDFchevron_right
Radioimmunotheranostic Pair Based on the Anti-HER2 Monoclonal Antibody: Influence of Chelating Agents and Radionuclides on Biological Properties
Luiza Mascarenhas Balieiro
Pharmaceutics
View PDFchevron_right
Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules
Joachim Feldwisch
2016
View PDFchevron_right
Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment
Alberto Juan
International Journal of Molecular Sciences, 2020
View PDFchevron_right
Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer
Nick Devoogdt , M. Keyaerts , Matthias D'Huyvetter , I. Vaneycken , Cécile Vincke
Journal of Nuclear Medicine, 2013
View PDFchevron_right
64Cu-Labeled Affibody Molecules for Imaging of HER2 Expressing Tumors
Jack Berman Webster
Molecular Imaging and Biology, 2009
View PDFchevron_right
HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches
Davide Prosperi
Pharmacological Research, 2010
View PDFchevron_right
HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment
Francesco Mainini
Cancers
View PDFchevron_right
Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies
Antero Abrunhosa
International Journal of Molecular Sciences, 2021
View PDFchevron_right
On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model
Anna Orlova , Vladimir Tolmachev
Journal of Nuclear Medicine, 2009
View PDFchevron_right
HER-2-Targeted Nanoparticle-Affibody Bioconjugates for Cancer Therapy
Frank Alexis
ChemMedChem, 2008
View PDFchevron_right
Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors
Paul M. P. Bergen Henegouwen
Frontiers in immunology, 2017
View PDFchevron_right
Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors
Tran Thuy
Cancer Research, 2007
View PDFchevron_right
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
Joachim Feldwisch
Journal of Nuclear Medicine, 2014
View PDFchevron_right
HER2-Positive Tumors Imaged Within 1 Hour Using a Site-Specifically 11C-Labeled Sel-Tagged Affibody Molecule
Erik Samén
Journal of Nuclear Medicine, 2012
View PDFchevron_right
Preclinical Targeted α- and β−-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
Janik Puttemans
Cancers
View PDFchevron_right
In Vitro Characterization of a Bivalent Anti-HER-2 Affibody with Potential for Radionuclide-Based Diagnostics
Grégory ADAMS
Cancer Biotherapy and Radiopharmaceuticals, 2005
View PDFchevron_right